Montreux Capital Management (UK) has secured the merger of The Huntercombe Group with the Montreux Healthcare Fund’s operating asset, The Active Care Group in an historic deal which will add over c.£13m EBITDA.

The merger will secure 14 freehold properties and c.390 service users for the business, adding a mental health specialism to The Active Care Group’s already strong learning disability and neurological injury specialisms. The deal places the group on a strong footing, with significant synergies and organic growth anticipated in 2022 as a result of the businesses coming together.

Oliver Harris, Managing Partner, Montreux Capital Management (UK) stated: “The merger of these two businesses is a crucial step forward for The Active Care Group and the Montreux Healthcare Fund. The Huntercombe Group is a very high-quality business with a strong senior leadership team which will complement The Active Care Group’s already strong business model. Importantly, the merger should deliver significant value to the fund’s investors.”

Dr Sylvia Tang, CEO, The Active Care Group remarked: “This is a fantastic opportunity to bring our wealth of clinical strength and expertise together to deliver the best care and outcomes for individuals in the right settings – in hospital, residential care, supported living or at home. We are very excited to come together to deliver continuous improvement in the care we deliver.”

Find Us

Thameside House
Hurst Road
East Molesey

T: + 44 (0) 1932 860 140

Information on this webpage relates to and is provided by Montreux Capital Management (UK) Limited

The content of this webpage should not be construed as financial advice. Any decision to invest should be made only on the basis of the relevant documentation for each investment. Past performance is not necessarily a guide to future performance. The value of an investment may go down as well as up and investors may not get back the full amount invested. Investments in small unquoted companies carry an above-average level of risk. These investments are highly illiquid and as such, there may not be a readily available market to sell such an investment. Montreux Capital Management (UK) Limited and Sapia Partners LLP (together “the Sponsors,” or “Sponsor”) do not provide specific individual advice on the suitability of investments with regard to a potential investor’s individual circumstances, risk tolerance or investment objectives and investors should seek independent financial advice if they are in any doubt whether a product is suitable for them.

Montreux Capital Management (UK) Limited is an Appointed Representative of Sapia Partners LLP which is authorised and regulated by the Financial Conduct Authority.